Trials / Completed
CompletedNCT00284518
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 380 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | botulinum toxin Type A | Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1. |
| DRUG | normal saline | Normal Saline (Placebo) transperineal or transrectal injection on Day 1. |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2009-05-01
- Completion
- 2010-05-01
- First posted
- 2006-02-01
- Last updated
- 2012-12-17
- Results posted
- 2012-12-17
Locations
11 sites across 11 countries: Australia, Austria, Canada, Czechia, France, Germany, Italy, Slovakia, South Korea, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00284518. Inclusion in this directory is not an endorsement.